Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Urogenital Cancer Genitourinary Cancer—Prostate, Testicular, and Penile

Genitourinary Cancer—Prostate, Testicular, and Penile

The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer.
 
Alistair Grey, Rebecca Scott, Bina Shah, et al.
Clinical trial information: 38541912.
 
MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.
 
Taimur T. Shah, Abi Kanthabalan, Menelaos Pavlou, et al.
 Clinical trial information: NCT01883128
 
Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).
 
Alan Dal Pra, Pirus Ghadjar, Stefanie Hayoz, et al.
 
 
Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.
 
Anthony Victor D'Amico, Wanling Xie, Elizabeth McMahon, et al.
Clinical trial information: NCT00116142
 
Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).
 
Sean Matthew McBride, Daniel Eidelberg Spratt, Marisa Kollmeier, et al.
 Clinical trial information: NCT02772588
 
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Johann S. De Bono, Lawrence Fong, Tomasz M. Beer, et al.
Clinical trial information: NCT03577028
 
COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Mark Christopher Markowski, Mary-Ellen Taplin, Rahul Raj Aggarwal, et al.
 Clinical trial information: NCT03554317
 
Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
 
Scott T. Tagawa, Michael Sun, A. Oliver Sartor, et al.
Clinical trial information: NCT03276572
 
Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.
 
Shirin Ardeshirrouhanifard, Sophie Fosså, Robert A Huddart, et al.
 
 
Immunity to childhood vaccines following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for germ cell tumors (GCT) with comparison to Hodgkin lymphoma (HL).
 
Darren R. Feldman, Akeem Ronell Lewis, Andrea Knezevic, et al.
 
 
Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).
 
Jennifer King, Sandra K. Althouse, Clint Cary, et al.
 
 
Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.
 
Andreas Georg Wibmer, Darren R. Feldman, Carol Chen, et al.